Current Report Filing (8-k)
09 Mai 2014 - 12:11PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
May 8, 2014
BIOSCRIP, INC.
(Exact name of Registrant as specified in
its charter)
Delaware |
|
000-28740 |
|
05-0489664 |
(State of Incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer
Identification No.) |
100 Clearbrook Road, Elmsford, New York |
|
10523 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including
area code: (914) 460-1600
N/A
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Section 2 – Financial Information
Item 2.02 Results of Operations and Financial Condition.
On May 8, 2014, BioScrip, Inc. (the “Company”) issued
a press release reporting its 2014 first quarter financial results. A copy of the press release is furnished with this Current
Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.
Section 8 – Other Events
Item 8.01. Other Events.
As previously announced, the Company will host a conference
call to discuss its 2014 first quarter financial results on May 9, 2014 at 8:30 a.m. Eastern Time. Interested parties may participate
in the conference call by dialing 800-896-0105 (U.S.) or 212-231-2922 (International) 5-10 minutes prior to the start of the call.
A replay of the conference call will be available for two weeks after the call's completion by dialing 800-633-8284 (U.S.) or 402-977-9140
(International) and entering conference call ID number 21715187. An audio webcast and archive will also be available for 30 days
under the “Investor Relations” section of the Company’s website at www.bioscrip.com.
The press release includes certain non-GAAP financial measures
as described therein. As required by Regulation G, reconciliation between any non-GAAP financial measures presented and the most
directly comparable GAAP financial measures is also provided.
Section 9 – Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits. See the Exhibit Index which is hereby incorporated
by reference.
As provided in General Instruction B.2 to Form 8-K, the information
furnished in Item 2.02 and in Exhibit 99.1 hereto as it relates to the Company’s financial results for the quarter ended
March 31, 2014, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended
(the “Exchange Act”), or otherwise subject to the liabilities under that Section and shall not be deemed incorporated
by reference into any filing of the Company with the Securities and Exchange Commission under the Securities Act of 1933, as amended,
or the Exchange Act, except as shall be expressly provided by specific reference in such filing.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
BIOSCRIP, INC. |
|
|
|
Date: May 8, 2014 |
|
|
|
/s/ Kimberlee C. Seah |
|
|
By: |
|
Kimberlee C. Seah |
|
|
|
|
Senior Vice President and General Counsel
|
Exhibit
Index
Exhibit No. |
Description |
|
|
99.1 |
BioScrip, Inc. press release dated May 8, 2014 |
BioPlus Acquisition (NASDAQ:BIOS)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
BioPlus Acquisition (NASDAQ:BIOS)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024